Outset Medical, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of TabloCartTM with prefiltration, an innovative optional accessory for the Tablo® Hemodialysis System . Outset has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the United States. TabloCart is designed to enhance the user experience within healthcare facilities.

It comes in two versions: one with added storage and another featuring water prefiltration capabilities, meeting diverse clinical needs. Key features of TabloCart include: Versatile prefiltration: With its three customizable prefiltration options, TabloCart is designed to adapt to varying water conditions and also features a booster pump to increase incoming water pressure. Enhanced maneuverability: Equipped with 360-degree rotating wheels and directional locking rear wheels, it facilitates seamless movement through various clinical environments.

TabloCart is an innovative optional accessory that complements the Tablo Hemodialysis System. Tablo, which is used from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients, and operationally simplifies it for providers. Requiring only access to tap water and a standard electrical outlet, Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone.